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ABSTRACT
Objectives To validate the clinical efficacy and practical
feasibility of massively parallel maternal plasma DNA
sequencing to screen for fetal trisomy 21 among high risk
pregnancies clinically indicated for amniocentesis or
chorionic villus sampling.
Design Diagnostic accuracy validated against full
karyotyping, using prospectively collected or archived
maternal plasma samples.
Setting Prenatal diagnostic units in Hong Kong, United
Kingdom, and the Netherlands.
Participants 753 pregnant women at high risk for fetal
trisomy 21 who underwent definitive diagnosis by full
karyotyping, of whom 86 had a fetus with trisomy 21.
InterventionMultiplexed massively parallel sequencing
of DNA molecules in maternal plasma according to two
protocols with different levels of sample throughput:
2-plex and 8-plex sequencing.
Main outcome measures Proportion of DNA molecules
that originated from chromosome 21. A trisomy 21 fetus
was diagnosed when the z score for the proportion of
chromosome 21 DNA molecules was >3. Diagnostic
sensitivity, specificity, positive predictive value, and
negative predictive value were calculated for trisomy 21
detection.
Results Results were available from753 pregnancieswith
the 8-plex sequencing protocol and from314pregnancies
with the 2-plex protocol. The performance of the 2-plex
protocol was superior to that of the 8-plex protocol. With
the 2-plex protocol, trisomy 21 fetuses were detected at
100% sensitivity and 97.9% specificity, which resulted in
a positive predictive value of 96.6% and negative
predictive value of 100%. The 8-plex protocol detected
79.1% of the trisomy 21 fetuses and 98.9% specificity,
giving a positive predictive value of 91.9% and negative
predictive value of 96.9%.
ConclusionMultiplexed maternal plasma DNA
sequencing analysis could be used to rule out fetal
trisomy 21 among high risk pregnancies. If referrals for
amniocentesis or chorionic villus samplingwere based on
the sequencing test results, about 98% of the invasive
diagnostic procedures could be avoided.
INTRODUCTION
Trisomy 21, Down’s syndrome, occurs in 1 in 800 live
births.1 Prenatal diagnosis of trisomy 21 requires inva-
sive sampling of fetal genetic material through amnio-
centesis or chorionic villus sampling. However, these
tests carry a risk of miscarriage of about 1%,2 and they
are therefore reserved for pregnancies considered to be
at high risk of fetal trisomy 21. The traditional method
of identifying the high risk group has been increased
maternal age, but screening by this method would
require invasive testing in about 5% of pregnant
women and identify only 30% of affected fetuses.1 In
the past 20 yearsmaternal age has been combinedwith
ultrasonographic examination of the fetus and bio-
chemical measurement of various proteins or hor-
mones in the maternal circulation to improve
identification of high risk pregnancies. This combined
approach of screening can now identifymore than 90%
of affected fetuses, but there is still a need for invasive
testing in 3–5% of the population.3-9
Cell-free DNA from the fetus has been found in the
plasma of pregnant women, and this has been used
successfully for non-invasive determination of the
fetal sex and fetal RhD genotype in RhD negative
women.10-13 The basis of these tests is the detection of
fetal-specific DNA sequences in maternal plasma.14
The same approach of searching for fetal-specific
nucleic acids, such as DNA methylation and mRNA
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markers in maternal plasma, has been proposed for
non-invasive detection of fetal aneuploidies.15-19
The advantages and disadvantages of these
approaches have been reviewed in detail.20 An alterna-
tive approach for non-invasive prenatal diagnosis of
fetal trisomy 21 is to show the presence of an elevated
amount of chromosome 21 sequences in maternal
blood, because there are three rather than two copies
of fetal chromosome 21.18 However, fetal DNA mole-
cules amount to just 10–20% of the total DNA circulat-
ing in the maternal plasma,21 22 so any increment in the
total amount (fetal and maternal) of chromosome 21
DNA molecules in the plasma of a trisomy 21 preg-
nancy would be substantially diluted by contributions
from the mother.20
Thedifficulty inmeasuring such a small increment in
chromosome21DNAconcentration has recently been
overcome with the use of massively parallel genomic
sequencing.20 This technique can identify and quantify
millions of DNA fragments in biological samples in a
span of days.23 Three cohort studies have shown the
feasibility of using the technique to identify fetuses
with trisomy 21 by analysis of maternal plasma
DNA.24-26 The sample numbers studied were small
because, typically, only a few samples could be ana-
lysed in each sequencing run.
The objective of this study is to validate the diagnos-
tic performance and practical feasibility of massively
parallel genomic sequencing for the non-invasive pre-
natal assessment of trisomy 21 in a large number of
pregnancies that have undergone conventional screen-
ing and were clinically indicated for definitive testing
by amniocentesis or chorionic villus sampling.
METHODS
Theprimary research question of the studywas to eval-
uate if maternal plasma DNA sequencing could accu-
rately confirm or exclude fetal trisomy 21 compared
with full karyotyping among pregnancies clinically
indicated for amniocentesis or chorionic villus sam-
pling. A secondary goal of the study was to develop
laboratory protocols to improve the throughput of
massively parallel genomic sequencing for handling
large sample numbers.
Recruitment criteria
We prospectively recruited pregnant women from
eight obstetric units in Hong Kong, one unit from the
Netherlands, and one prenatal diagnostic centre in the
United Kingdom between October 2008 and May
2009. We also retrieved archived maternal plasma
samples collected betweenOctober 2003 and Septem-
ber 2008 from trisomy 21 and non-trisomy 21 preg-
nancies matched for gestational ages in a ratio of
approximately 1:5 from the participating sites in the
Netherlands and UK. The inclusion criteria were sin-
gleton pregnancies with clinical indications for chorio-
nic villus sampling or amniocentesis as per the existing
obstetric practice of each recruitment unit. Women
were excluded if full karyotyping results were not
available.
We recorded the maternal ages at the expected time
of delivery, gestational ages at blood sampling, and
indications for invasive testing.
Sample processing
Peripheral venous blood samples (5–10 mL) were col-
lected into tubes containing EDTA. A plasma sample
would be accepted for analysis if it was collected before
invasive obstetric procedures, was harvestedwithin six
hours of venepuncture, was at least 2 mL in volume,
and was not haemolysed. The prospectively collected
and retrieved archival plasma samples from the UK
and the Netherlands were sent to Hong Kong in
batches by overnight courier while kept frozen on dry
ice. We performed all subsequent analyses prospec-
tively at The Chinese University of Hong Kong.
Maternal plasma DNA sequencing
We extracted and sequenced DNA molecules from
2.0–4.8mLofmaternal plasma using a protocol similar
to that reported previously but with the introduction of
multiplexing.24 27 DNA molecules exist in maternal
plasma as short fragments. The genomic identities of
millions of DNAmolecules per maternal plasma sam-
ple can be decoded in a sequencing run. The analytical
goal of our test was to determine the proportion of
sequenced plasma DNA molecules originating from
chromosome 21 (percentage chromosome 21). This
proportion is expected to be elevated in maternal
plasma during a pregnancy with a trisomy 21 fetus.
Multiplexing allows more than one plasma sample to
be mixed and sequenced jointly in each discrete seg-
ment of a sequencing glass slide and thereby increases
the number of samples that can be analysed in each
sequencing run.We studied two levels ofmultiplexing,
2-plex and 8-plex, whereby DNA from two or eight
maternal plasma samples were co-sequenced in each
slide segment.
Briefly, a unique synthetic DNA “barcode” of six
base pairs, referred to as an index, was introduced on
to one end of each plasma DNA molecule. The index
served as a signature for a sample, with one index used
per maternal plasma sample. For example, for 8-plex
sequencing, eight different indices were needed for
each of the eight test or control samples that would be
co-sequenced. We compiled the multiplexed sample
mixtures by pooling eight or two maternal plasma
DNA preparations for the 8-plex or 2-plex sequencing
protocols.
Weperformed sequencing on theGenomeAnalyzer
II (Illumina) for the 8-plex samplemixtures and on the
GenomeAnalyzer IIx (Illumina) for the 2-plex sample
mixtures. After the sequencing run, the actual DNA
molecules that belonged to a specific sample could
then be distinguished from those belonging to other
samples by sorting the index sequences attached to
the DNA molecules. We considered a sequencing
result as valid and reportable only if the analysis of
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the sample passed a set of quality control measures
(listed in appendix 1).
Sequencing data analysis
We processed the sequencing data with the use of a
bioinformatics algorithm based on our previously
reported strategy (appendix 2 on bmj.com).24 In
essence, the chromosomal origin of each sequenced
“read” (the short fragments of DNA that are decoded)
was identified by comparingwith the reference human
genome available from the Ensembl website (ftp://ftp.
ensembl.org/pub/release-48/fasta/homo_sapiens/
dna/). The percentage chromosome 21 within each
maternal plasma sample was then calculated. The pro-
portion of reads from chromosome Y (percentage
chromosome Y) was similarly calculated and was
used to estimate the fetal DNA concentrations (that
is, the proportion of DNA molecules in the maternal
plasma sample that originated from the fetus) in preg-
nancies with male fetuses. We derived a z score for
chromosome 21 in a test sample by subtracting the
mean percentage chromosome 21 of a reference set
of euploid pregnancies (controls) from the percentage
chromosome 21 of the test case and divided by the
standard deviation of the value for percentage chromo-
some 21 among the reference sample set according to
the equation:
Z score for percentage chromosome 21 in test case =
((percentage chromosome 21 in test case) − (mean
percentage chromosome 21 in reference controls))/
(standard deviation of percentage chromosome 21 in
reference controls).
We used a z score of >3 (representing a percentage
chromosome 21 value greater than that of the 99.9th
centile of the reference sample set for a one tailed dis-
tribution) as the cut-off value to determine if the per-
centage chromosome 21 was increased and hence fetal
trisomy 21 was present.
All members of the sequencing and bioinformatics
teams were blinded to the karyotype information. Dis-
ease classification based on the sequencing results and
z scores was generated automatically by the bioinfor-
matics algorithm. We then determined the diagnostic
performance of the sequencing test by comparing its
results with those of full karyotyping of the amniotic
fluid or chorionic villus sample.
Statistical analysis
We reported the observed diagnostic sensitivity and
specificity values of the sequencing protocols based
on the predefined cut-off point—namely, chromosome
21 z score of 3.We plotted the receiver operating char-
acteristic (ROC) curves for the measurements of per-
centage chromosome 21 and determined the areas
under the curves (AUC). ROC curve analysis was
also performed to derive cut-off values for percentage
chromosomeY to distinguish male and female fetuses.
Wemeasured the analytical imprecision of the sequen-
cing protocols by calculating the coefficient of varia-
tion (SD/mean × 100%) of the percentage
chromosome 21 values among the control samples.
The normality of quantitative variables was analysed
with the use of the Kolmogorov-Smirnov test.We then
used Student’s t test or Mann-Whitney test and Pear-
son’s correlation as appropriate. Two sided P values of
<0.05 were considered to indicate statistical signifi-
cance. ROC curve analyses were performed with the
use of theMedCalc software (version 9.6.4.0).All other
statistical calculations were performed with the use of
the SigmaStat software (version 3.11).
RESULTS
Study participants
We recruited 576 pregnant women prospectively and
retrieved archived maternal plasma samples from 248
women, which amounted to a total of 824 pregnancies
(fig 1). Fourteen pregnant women (1.7%) did not meet
the recruitment criteria, and 46 maternal plasma sam-
ples (5.6%) did not pass the specimen quality require-
ments. The quality control requirements were not met
during the sequencing of 11 (1.4%) maternal plasma
samples (appendix 1). Analytically valid sequencing
results thatmet the criteria for reportingwere achieved
for 753 maternal plasma samples with the use of the
8-plex protocol. The characteristics of these pregnan-
cies are shown in table 1. Themedianmaternal agewas
Pregnancies with maternal blood sampling (n=824)
Maternal blood samples (n=764)
Pregnancies with valid results from 8-plex sequencing (n=753)
Euploid fetus (n=597) Other fetus: 
  Trisomy 18 (n=40)
    (13 with 2-plex*)
  Trisomy 13 (n=20)
    (16 with 2-plex*)
  Turner’s syndrome (n=8)
    (0 with 2-plex*)
  Sex chromosome mosaic (n=2)
    (1 with 2-plex*)
Trisomy 21 fetus (n=86)
(86 with 2-plex*)
Non-trisomy 21 case (n=571)
(146 with 2-plex*)
Reference controls (n=96)
(82 with 2-plex*)
*No of cases with sequencing results from 2-plex protocol
Test case (n=501)
(116 with 2-plex*)
Sample failed quality control for sequencing (failed DNA
extraction, library preparation, or sequencing) (n=11)
Failed recruitment criteria (n=14):
  Twin pregnancy (n=2)
  Without full karyotyping (n=12)
Compromised blood sample (n=46):
  Sample collected after invasive obstetric procedure (n=3)
  Delayed blood processing (n=2)
  With ambiguous information (n=3)
  Haemolysed (n=12)
  Inadequate volume (n=26)
Fig 1 | Recruitment of participants. Numbers in parentheses are the number of cases with
sequencing results from the 2-plex protocol
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35.4 years, and the median gestational age at the time
of maternal blood sampling was 13 weeks and 1 day.
Full karyotyping showed that there were 86 preg-
nancies with trisomy 21 fetuses (40 cases from the
archival sample set) and 597 pregnancies with euploid
fetuses (fig 1). The remainder comprised 40 fetuses
with trisomy 18, 20 with trisomy 13, eight with Turn-
er’s syndrome, and two sex chromosome mosaics, all
of which were included as non-trisomy 21 cases in this
study.
Among the sequenced samples, we randomly chose
96 pregnancies with euploid male fetuses as the refer-
ence control set for z score calculation. All 86 trisomy
21 cases, 82 reference controls, and 146 non-trisomy
21 cases were sequenced with the 2-plex protocol
(fig 1).
Review of the clinical profile of the cases revealed
there were three broad groups of clinical indications
for referral for full karyotyping: (a) pregnancies with
a risk higher than 1 in 300 for fetal trisomy 21 as esti-
mated by conventional prenatal screening; (b) preg-
nancies with an intermediate risk (risk between 1 in
300 and 1 in 1000) for fetal trisomy 21; and (c) pregnan-
cies with other risk indications, including a previous
trisomy 21 pregnancy, ultrasound abnormalities, or
risks formonogenic diseases. Thenumbers of pregnan-
cies in the high, intermediate, and other risk groups
were 582, 39, and 132, respectively (table 1). Among
the high and intermediate risk groups, 570 (91.8%)
pregnant women underwent combined screening in
the first trimester while the remaining 51 (8.2%)
women received other forms of prenatal screening,
including the integrated test and second trimester
maternal serum screening.
Diagnostic performance of maternal plasma DNA
sequencing
A mean of 0.3 million (SD 88 000) reads per sample
from the 8-plex sequencing analysis and 2.3 million
(SD 474 000) from 2-plex sequencing matched our
bioinformatics criteria for calculation of percentage
chromosome 21. As each sequencing glass slide can
sequence only a finite number of DNA molecules,
higher levels of multiplexing would lead to fewer
DNA molecules to be sequenced per sample. Figure
2 shows the distribution of the chromosome 21 z scores
among the controls, non-trisomy 21 group, and tris-
omy 21 group. Table 2 summarises the diagnostic per-
formance of the sequencing test for detecting fetal
trisomy 21.
With a chromosome 21 z score of 3 as the diagnostic
cut-off point, the 2-plex protocol detected 100% of tris-
omy 21 fetuses at a 2.1% false positive rate—namely,
100% sensitivity and 97.9% specificity. This gave a
positive predictive value of 96.6% and a negative pre-
dictive value of 100%.
The 8-plex protocol, however, detected 79.1% of the
trisomy 21 fetuses at a false positive rate of 1.1%—that
is, 79.1% sensitivity and 98.9% specificity. The positive
predictive valuewas 91.9% and the negative predictive
Table 1 | Characteristics of 753 pregnancies with maternal plasma DNA sequencing. Values
are numbers (percentages) of subjects unless stated otherwise
Characteristic
Reference
controls (n=96)*
Non-trisomy 21
fetuses (n=571)
Trisomy 21
fetuses (n=86)
All
(n=753)
Fetal sex:
Male 96 (100) 251 (44) 39 (45) 386 (51)
Female 0 318 (56) 47 (55) 365 (48)
Sex chromosome mosaic 0 2 (0.4) 0 2 (0.3)
Maternal age at expected date of
delivery (years):
<35 42 (44) 255 (45) 22 (26) 319 (42)
≥35 54 (56) 316 (55) 64 (74) 434 (58)
Median age 35.7 35.0 38.0 35.4
Gestational age at maternal blood
sampling (weeks+days):
≤13+6 80 (83) 410 (72) 67 (78) 557 (74)
>14+0 to 14+6 7 (7) 80 (14) 15 (17) 102 (14)
>15+0 9 (9) 81 (14) 4 (5) 94 (12)
Median gestational age 12+5 13+1 13+0 13+1
Means of invasive testing:
Chorionic villus sampling 78 (81) 462 (81) 81 (94) 621 (82)
Amniocentesis 18 (19) 109 (19) 5 (6) 132 (18)
Risk grouping:
High 64 (67) 437 (77) 81 (94) 582 (77)
Intermediate 6 (6) 33 (6) 0 39 (5)
Other 26 (27) 101 (18) 5 (6) 132 (18)
Median fetal risk for trisomy 21:
In high risk group 1 in 50 1 in 51 1 in 2 1 in 43
In intermediate risk group 1 in 486 1 in 513 NA 1 in 502
*Euploid male fetuses. NA=not applicable.
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Fig 2 | Z scores of percentage chromosome 21 (proportion of
sequenced plasma DNA molecules originating from
chromosome 21) determined by the 8-plex and 2-plex
sequencing protocols. Broken lines indicate the z score
cut-off value of 3
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value was 96.9%. Eleven of the 18 false negative cases
were from the archived samples. The distribution of
the false negative and true positive cases among the
prospectively collected and archived samples was not
statistically significant (χ2 test, P=0.258). The median
gestational ages for the true positive and false negative
trisomy 21 cases from the 8-plex protocol were
13.0 weeks (interquartile range 12.3–13.5) and
12.9 weeks (12.3–13.5), respectively. The median risk
level for trisomy 21 estimated by conventional screen-
ing for the true positive and false negative cases were 1
in 4 (interquartile range 1 in 5 to 1 in 2) and 1 in 5 (1 in 7
to 1 in 2), respectively. The true positive and false nega-
tive cases were not significantly different in terms of
gestational ages (Mann-Whitney, P=0.538) or risk
levels (Mann-Whitney, P=0.466). There were six false
positive results in the 8-plex results and three in the
2-plex results. Because of the small number of false
positive cases, no systematic features were identified.
Profiles of these cases are shown in appendix 3 on
bmj.com.
ROC curve analysis of the percentage chromosome
21measurements for all test cases was done to estimate
the diagnostic efficacy of the 2-plex and 8-plex sequen-
cing protocols (fig 3). Area under the curve values for
the 2-plex and 8-plex sequencing protocols were 1.00
(95% confidence interval 0.98 to 1.00) and 0.98 (0.97 to
0.99) respectively.
Utility of maternal plasma DNA sequencing for the prenatal
assessment of trisomy 21
In this study we focused on pregnancies clinically indi-
cated for invasive prenatal diagnostic testing because
we required the availability of full karyotyping for
comparison of the diagnostic performance of the
sequencing test. However, this study design essentially
limits the applicability of our data to pregnancies at
increased risk for trisomy 21. To investigate if the
sequencing test might be useful as a screening test for
all pregnancies in general, we determined the post-test
probabilities for women of different ages and hence
with different prevalences of trisomy 21.28 The data
are shown in table 3. For a 20 year old woman at
12 weeks of gestation, her pretest probability for tris-
omy 21 by maternal age alone was 1 in 1068. If mater-
nal plasma DNA sequencing with the 2-plex protocol
was done, the post-test probability for a positive test
result was 1 in 23 while the post-test probability for a
negative test result was 1 in infinity. With the 8-plex
protocol, the post-test probabilities for a positive result
and a negative result becomes 1 in 16 and 1 in 5082
respectively.
These data suggest that the sequencing test result,
whether positive or negative, can substantially alter
the probabilities for having a trisomy 21 fetus. The 2-
Table 2 | Diagnostic performance of maternal plasma DNA sequencing for detecting fetal trisomy 21 and fetal sex
8-plex sequencing protocol 2-plex sequencing protocol
True detection rate False positive rate True detection rate False positive rate
Trisomy 21 detection* Among 86 trisomy 21 cases Among 571 non-trisomy 21 cases Among 86 trisomy 21 cases Among 146 non-trisomy 21 cases
79.1% (68/86) 1.1% (6/571) 100% (86/86) 2.1% (3/146)
Fetal sex (male) detection† Among 386 male fetuses Among 365 female fetuses Among 196 male fetuses Among 117 female fetuses
99.5% (384/386)
(95% CI 98.1% to 99.9)
0.8% (3/365)
(95% CI 0.2% to 2.4%)
99.5% (195/196)
(95% CI 97.2% to 99.9%)
0.8% (1/117)
(95% CI 0.1% to 4.7%)
*Z score for percentage chromosome 21 >3.
†Cut-off values for percentage chromosome Y identified by ROC analysis.
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Fig 3 | Diagnostic efficacy of diagnosis of fetal trisomy 21 by
sequencing of maternal plasma DNA according to 8-plex and
2-plex protocols. Receiver operating characteristic (ROC)
curves (faint lines showing 95% confidence intervals) for
measurements of percentage chromosome 21
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plex sequencing particularly highlights the key value
of the sequencing test result for ruling out trisomy 21.
Factors affecting diagnostic performance
The diagnostic performance of the 2-plex protocol was
superior to that of the 8-plex sequencing, with signifi-
cantly higher z score values for the trisomy 21 cases
(Mann-Whitney, P<0.001). The high z scores were
due to a small standard deviation and, hence, better
precision for estimating percentage chromosome 21.
The coefficients of variation of percentage chromo-
some 21 values for the controls on each flow cell
were calculated as a measure of precision (see appen-
dix 4 on bmj.com). The mean coefficient of variation
for measuring percentage chromosome 21 with the
8-plex protocol was 1.59% (SD 0.36%) and was higher
than that for the 2-plex protocol, which was 0.66% (SD
0.25%) (t test, P<0.001).
The extent of increase in percentage chromosome
21 in maternal plasma for the trisomy 21 cases is gov-
erned by the fetal DNA concentration. We calculated
the fetal DNA concentrations based on the percentage
chromosome Y values among the 39 male fetuses with
trisomy 21 and plotted them against the chromosome
21 z scores (shown in appendix5onbmj.com).The two
variables are significantly correlated in both the 8-plex
sequencing data (Pearson correlation coefficient 0.703,
P<0.0001) and 2-plex data (Pearson correlation coeffi-
cient 0.462, P=0.003). The five pregnancies with male
fetuseswith trisomy21 thatwe failed to detect using the
8-plex protocol (that is, with chromosome 21 z scores
<3) had fetal DNA concentrations less than 10%.
Theoretically, at 10% fetal DNA concentration, per-
centage chromosome 21 is just 1.05 times higher in a
plasma sample obtained from a trisomy 21 pregnancy
than a euploid pregnancy.18 To detect this increase in
percentage chromosome 21, the coefficient of varia-
tion of the test would need to be ≤0.83% (see appendix
6 on bmj.com). Themean coefficient of variation of the
8-plex protocol was greater than this value, whereas
that of the 2-plex protocol was <0.83%. Hence, the
2-plex protocol performed better at detecting trisomy
21 among samples containing low fetal DNA concen-
trations.
Fetal sex determination by maternal plasma DNA
sequencing
The presence of chromosome Y sequences among
sequenced DNA molecules from maternal plasma
should theoretically signify that the pregnancy
involved a male fetus. However, we previously
reported that the bioinformatics algorithm would
incorrectly assign a small fraction of sequenced DNA
reads to chromosome Y in pregnancies with female
fetuses.24 The percentage chromosome Y values of all
studied pregnancies are shown in appendix 7 on
bmj.com. Optimal cut-off values for percentage chro-
mosomeY to distinguishmale and female fetuses were
identified by ROC curve analysis to be 0.0114% and
0.0095% for the 8-plex and 2-plex protocols, respec-
tively. Table 2 shows the estimated diagnostic perfor-
mance for fetal sex determination. We then
determined the fetal DNA concentrations of 314 preg-
nancies with euploidmale fetuses based on the percen-
tage chromosome Y values obtained from the 8-plex
protocol. The median fetal DNA concentration was
15.2% (interquartile range 10.6%–19.1%), and the dis-
tribution is shown in fig 4.Among the pregnancieswith
euploidmale fetuses, themedian fetal DNAconcentra-
tion for the archival and prospectively collected sam-
ples were 14.7% and 15.4%, respectively (Mann-
Whitney, P=0.334).
Table 3 | Probabilities for a trisomy 21 fetus in women by age alone and according to result of maternal plasma DNA
sequencing test
Maternal age
(years) Pretest probability*
Post-test probability
8-plex sequencing 2-plex sequencing
Positive test result† Negative test result Positive test result† Negative test result
20 1 in 1068 1 in 16 1 in 5082 1 in 23 1 in infinity
25 1 in 946 1 in 14 1 in 4501 1 in 21 1 in infinity
30 1 in 626 1 in 10 1 in 2977 1 in 14 1 in infinity
31 1 in 543 1 in 9 1 in 2582 1 in 12 1 in infinity
32 1 in 461 1 in 7 1 in 2191 1 in 11 1 in infinity
33 1 in 383 1 in 6 1 in 1820 1 in 9 1 in infinity
34 1 in 312 1 in 5 1 in 1482 1 in 8 1 in infinity
35 1 in 249 1 in 4 1 in 1182 1 in 6 1 in infinity
36 1 in 196 1 in 4 1 in 930 1 in 5 1 in infinity
37 1 in 152 1 in 3 1 in 720 1 in 4 1 in infinity
38 1 in 117 1 in 3 1 in 553 1 in 3 1 in infinity
39 1 in 89 1 in 2 1 in 420 1 in 3 1 in infinity
40 1 in 68 1 in 2 1 in 320 1 in 2 1 in infinity
41 1 in 51 1 in 2 1 in 239 1 in 2 1 in infinity
42 1 in 38 1 in 2 1 in 177 1 in 2 1 in infinity
*Pretest probabilities are based on prevalence of fetal trisomy 21 at 12th week of gestation.28
†A positive test result is a sample with a z score for percentage chromosome 21 >3.
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DISCUSSION
Weshow that fetal trisomy21 couldbedetected inhigh
risk pregnancieswith high sensitivity and specificity by
means of multiplexed sequencing of maternal plasma
DNA. A key strength of the study is that the diagnostic
performance was compared against full karyotyping,
which is the gold standard for aneuploidy diagnosis.
Another strength of this study is that the test perfor-
mance was assessed based on a large number of tris-
omy 21 and unaffected pregnancies. In fact, this study
reports the largest scale use of massively parallel geno-
mic sequencing (so called next generation sequencing)
formedical diagnostics to date and shows that it is prac-
tically feasible on a large scale.
Another strength of the study lies in the comparison
of the diagnostic performance of sequencing protocols
with two levels of sample throughput. The comparison
allows us to deduce factors that are fundamental to the
sensitive detection of fetal trisomy 21 and provide
insight into ways for further improvements. Measure-
ment of the percentage of plasma DNA that was from
chromosome 21 was more precise with the use of the
2-plex protocol because seven times more plasma
DNA molecules were analysed with this method than
with the 8-plex protocol. All trisomy 21 fetuses, includ-
ing those missed by the 8-plex protocol, were detected
with the 2-plex protocol. In short, the diagnostic sensi-
tivity of the sequencing approach improves with an
increase in the number of plasmaDNAmolecules ana-
lysed per sample.18
There are some weaknesses in the study design. Our
study was based on high risk pregnancies—those clini-
cally indicated for amniocentesis or chorionic villus
sampling—which ensured that full karyotyping results
were available from each pregnancy. To investigate if
the sequencing test might be useful for prenatal assess-
ment of fetal trisomy 21 for all pregnancies in general,
we determined the post-test probabilities for having a
trisomy 21 fetus in women of different ages, and hence
with different pretest risks. The data suggest that the
sequencing test result can substantially alter the prob-
abilities for having a trisomy 21 fetus even in women
with low pretest risk.
Another potential weakness of the study was that an
archived sample set was included. However, both the
prospectively collected and archived maternal plasma
samples were processed using the same protocols and
analysed prospectively. There were also no significant
differences in the fetal DNA concentrations and test
performances between the two sample groups. In this
study 5.6% of the collected maternal plasma samples
were of compromised quality. Reportable sequencing
resultswerenot achieved for 11 samples.All these sam-
ples were identified by the predefined quality control
steps. In routine practice, laboratory reports would not
be issued for such samples, and another blood speci-
men would be requested.
We found other aneuploidies besides trisomy 21
among the recruited pregnant women. For this study,
we focused on the diagnostic performance of the
sequencing approach for fetal trisomy 21 because our
previous data showed that the measurements of the
proportion of DNA molecules from chromosomes 18
and 13 were much less precise.24 25 More research is
required to develop protocols to improve the precision
for measuring amount of DNA molecules from chro-
mosomes 18 and 13.29
Our data reveal that the main value of the maternal
plasmaDNAsequencing test is to rule out fetal trisomy
21. Hence, with the current diagnostic performance, it
is more suitable as a screening test to stratify pregnan-
cies whose risk for trisomy 21 warrants the considera-
tion of amniocentesis or chorionic villus sampling. In
this study, we performed the sequencing test after a
pregnancy was deemed to be at increased risk for tris-
omy 21 according to the current prenatal screening
programmes. The false positive rates of the current
screening programmes are about 5%, and all of these
pregnanct women are offered the option of invasive
testing. However, if we took into consideration the
results of the sequencing test, trisomy 21 could be
ruled out in 98% of those pregnancies. This would
leave just 0.1% (that is, 5%×(100%−98%)×100%) of all
pregnant women needing referrals for amniocentesis
or chorionic villus sampling. Most of our studied preg-
nancieswere in the first trimester, which suggests that it
is possible to implement the test even in early preg-
nancy as a second tier screening test after the first tri-
mester combined test, which is already in use in many
parts of the world.
On the other hand, our post hoc analysis shows that
the sequencing test result may alter clinical decisions
even in women at low risk for trisomy 21. Hence, there
is the potential to apply the sequencing test as a first tier
screening test. However, massively parallel genomic
sequencing is currently expensive. To determine its
suitability as a first tier screening test would require
formal investigation of both its diagnostic performance
and cost benefit. We used the sequencing test in this
study for detection of fetal trisomy 21, but, with some
improvements in bioinformatics, it could be used to
detect other aneuploidies, such as trisomy 18 and tris-
omy 13.29 Furthermore, our group has recently shown
that when more sophisticated sequencing protocols
and bioinformatics algorithms are applied to the ana-
lysis of maternal plasma DNA, it may be possible to
Fetal DNA concentration (%)
Pr
op
or
ti
on
 o
f p
re
gn
an
ci
es
w
it
h 
eu
pl
oi
d 
m
al
e 
fe
tu
se
s 
(%
)
0
10
15
20
25
30
5
0-5 5-10 10-15 15-20 20-25 25-30 30-35 35-40
Fig 4 | Fetal DNA concentration found in maternal plasma
among pregnancies with euploid male fetuses
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 7 of 9
perform a genetic and mutational scan across the
whole genome of the fetus in a non-invasive
manner.30 Thus, it is likely that maternal plasma
DNA sequencing will play an increasingly important
role in the future developments of prenatal screening
and diagnosis.
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